Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -341.00K | -247.00K | -1.17M | -196.00K |
EBITDA | -49.15M | -43.27M | -64.57M | -46.09M | -33.78M |
Net Income | -44.60M | -40.42M | -64.81M | -47.13M | -33.51M |
Balance Sheet | |||||
Total Assets | 181.45M | 78.95M | 113.29M | 172.60M | 203.16M |
Cash, Cash Equivalents and Short-Term Investments | 170.29M | 65.58M | 84.37M | 91.23M | 168.60M |
Total Debt | 4.48M | 5.47M | 6.38M | 7.24M | 1.09M |
Total Liabilities | 14.32M | 10.63M | 11.21M | 10.68M | 3.91M |
Stockholders Equity | 167.13M | 68.32M | 102.08M | 161.91M | 199.24M |
Cash Flow | |||||
Free Cash Flow | -35.87M | -37.60M | -26.58M | -35.10M | -24.29M |
Operating Cash Flow | -35.81M | -37.56M | -26.46M | -34.50M | -23.41M |
Investing Cash Flow | 19.16M | 53.11M | 14.95M | -98.19M | 2.83M |
Financing Cash Flow | 139.87M | -91.00K | -90.00K | -228.00K | 189.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $116.23M | 34.76 | 10.42% | ― | 0.18% | -55.15% | |
51 Neutral | $7.35B | 0.50 | -65.61% | 2.47% | 15.28% | 1.44% | |
48 Neutral | $94.29M | ― | -179.12% | ― | 30.23% | -21.32% | |
43 Neutral | $92.81M | ― | -62.34% | ― | ― | 86.65% | |
39 Underperform | $118.06M | ― | -41.88% | ― | ― | 32.58% | |
38 Underperform | $105.66M | ― | -47.27% | ― | ― | 87.22% | |
36 Underperform | $115.44M | ― | -244.16% | ― | ― | 77.12% |
On April 26, 2025, Protara Therapeutics announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 in high-risk NMIBC patients. The trial demonstrated a 100% complete response rate at any time in BCG-Unresponsive patients and a 76% rate in BCG-Naïve patients, with favorable safety and tolerability profiles. These results, presented at the 2025 American Urological Association Annual Meeting, suggest TARA-002’s potential to significantly impact clinical practice by providing an effective alternative to radical cystectomy for NMIBC patients.
Spark’s Take on TARA Stock
According to Spark, TipRanks’ AI Analyst, TARA is a Underperform.
Protara Therapeutics’ stock score reflects the significant challenges faced by early-stage biotech companies. The absence of revenue and persistent cash outflows are major concerns, offset slightly by a strong equity position and low debt levels. Technical indicators suggest neutral momentum, while valuation metrics signal the typical struggles of a company focused on R&D without profitability. Overall, while the company may have potential, the current financial and operational metrics indicate high risk.
To see Spark’s full report on TARA stock, click here.